Profile 5: Crohn's Disease
In Crohn's disease the response to FMT is weaker than in colitis, so it stays investigational and shows the most promise in the biologic-naive, ileocolonic subgroup.
| Parameter | Crohn's-specific detail |
|---|---|
| Evidence level | ★★☆☆☆ Limited. Small RCTs and open-label series; inconsistent results. Active research area; FMT considered investigational in Crohn's outside specialist centers. |
| Mechanism of dysbiosis | Transmural inflammation; reduced microbial diversity; Enterobacteriaceae expansion (adherent-invasive E. coli); mucus layer disruption; abnormal Paneth cell function reducing antimicrobial peptide secretion. |
| Primary microbiota targets | Reduce AIEC (adherent-invasive E. coli) load. Restore Bacteroidetes diversity. Support ileal mucosal healing through F. prausnitzii enrichment. |
| Protocol modification | Full 4-phase protocol. Prolonged compatibility assessment may be indicated to identify optimal donor for transmural inflammatory profile. Colonoscopic induction with ileal intubation preferred where structurally feasible. |
| Minimum transfer duration | 60 days minimum; extended to 90+ days in partial responders with active disease. Crohn's mucosal remodeling requires longer integration time than UC. |
| Priority exposome focus | Ultra-processed food elimination (mucosal emulsifiers directly disrupt barrier in Crohn's). Specific Carbohydrate Diet or low-FODMAP modification as adjunct. Smoking cessation critical (smoking worsens Crohn's through microbial and immune mechanisms). Stress management. |
| Expected response timeline | More variable than UC or rCDI. Partial symptomatic improvement possible 4–6 weeks. Sustained benefit requires full consolidation. Non-response at 12 weeks warrants protocol review. |
| Warning signs (Crohn's-specific) | Perianal pain or discharge during consolidation (fistula). Fever + right lower quadrant pain (abscess). Obstructive symptoms (stricture). Significant CRP or fecal calprotectin rise after initial improvement. |
Table 16 – Clinical profile: Crohn's Disease # Protocol parameters, evidence level, and clinical modifications specific to Crohn's disease.
Sokol et al. 2024 (Lancet Gastroenterology & Hepatology) provides a current picture: Crohn-FMT response is substantially weaker than UC's (24% vs 36% at week 12), particularly in fistulizing and perianal Crohn forms [433]. The ECCO 2024 consensus does not recommend routine FMT in Crohn's disease [430].
Where Can FMT Have a Meaningful Role in Crohn's?
- Ileocolonic, biologic-naïve subgroup: Sokol 2024 strain-level analysis found Faecalibacterium prausnitzii Phylogroup II engraftment to be predictive — a targeted donor-screening criterion [433].
- Steroid weaning alongside anti-TNF therapy: emerging evidence that FMT may help avoid flare during steroid taper.
- Clinical trial protocols: traditionally multi-donor + longer (12-week) consolidation. Single-donor approach is less successful in Crohn's.
Contraindications in Crohn's
| Situation | Rationale |
|---|---|
| Active fistulizing disease | Bacterial colonization of fistula tract during FMT is risky |
| Severe stricturing disease | Mechanical occlusion compromises engraftment efficacy |
| Recent resection (<6 months) | Bowel wall remodeling in progress — FMT timing can wait |
| Active perianal disease | Locally contaminated area, increased infectious risk |
Patients must be informed that Crohn-FMT remains at the experimental level, and in many countries is available only under institutional protocol.
References
[430] Caenepeel C, Sokol H, Hold G et al. ECCO Topical Review: Use of Fecal Microbiota Transplantation in IBD. Journal of Crohn's and Colitis. 2024. Link
Caenepeel, Sokol, Hold and colleagues' 2024 Journal of Crohn's and Colitis ECCO Topical Review summarises the European Crohn's and Colitis Organisation (ECCO) consensus on the use of fecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD). The review aggregates RCT and meta-analytic evidence for ulcerative colitis (moderate-quality evidence, ~30% remission induction, multidonor and intensive-dose protocols superior) and Crohn's disease (limited evidence, signal in localised disease). The expert panel issues practical recommendations on patient selection, donor screening, delivery routes, dosing intensity, monitoring and ethical/legal considerations. The topical review is the operative ECCO reference for FMT in IBD, situating its role as a research-grade or selective clinical intervention pending further trials.
[433] Sokol H, Brot L, Stefanescu C et al. Fecal Microbiota Transplantation in Crohn's Disease: Updated Evidence and Practice Considerations. Lancet Gastroenterology \& Hepatology. 2024. Link
Sokol, Brot, Stefanescu and colleagues' 2024 Lancet Gastroenterology & Hepatology review summarises updated evidence and practice considerations for fecal microbiota transplantation (FMT) in Crohn's disease. The authors synthesise RCT and cohort data, including phase 2 trials suggesting modest benefit in colonic and localised Crohn's, with limited efficacy in fistulising or stricturing disease. Mechanistic studies highlight donor-strain engraftment, butyrate-producer recovery and reduced mucosal inflammation in responders. Practice considerations include patient selection (active inflammation, no abscess), dosing (intensive multidonor protocols), and integration with standard therapy. The review concludes that Crohn's FMT remains research-grade, pending larger phase 3 trials, and identifies priority research questions for the field.